Listen to this podcast to find out about CBT, or cognitive-behavioral therapy, and how therapists use it to treat anxiety and related disorders.
Carl "Chip" J. Lavie, MD
Professor of Medicine
Medical Director, Cardiac Rehabilitation and Prevention
Director, Stress Testing Laboratory
John Ochsner Heart and Vascular Institute
Ochsner Clinical School – The University of Queensland School of Medicine
New Orleans, Louisiana
Dr. Lavie, who practices cardiology and internal medicine, discusses the link between anxiety and other psychological stress for patients with cardiovascular disease.
Suffering from panic attacks in middle and high school, Solome couldn't find information online about her age group. So she started her own website.
I’m 21 years old, and besides my busy schedule as a full-time student the University of St. Thomas in St. Paul, Minnesota, keeping a regular running and yoga schedule, work, and trying to balance a social life, I am also the founder and Executive Director of Anxiety In Teens Non-Profit, LLC.Read
Melissa Hunt, PhD
Associate Director of Clinical Training
Department of Psychology, University of Pennsylvania
Adjunct Assistant Professor
Behavioral and Community Health
University of Pennsylvania School of Dental Medicine
Dr. Hunt discusses why many people with panic, agoraphobia, or social anxiety disorder also have IBS.
Karen Cassiday, PhD
Owner and Clinical Director
Anxiety and Agoraphobia Treatment Center, Ltd.
Dr. Cassiday discusses parents who often sabotage their children's development of self-esteem and self-confidence, but believe they are fostering a more caring relationship.
This study uses functional magnetic resonance imaging (fMRI) to learn how the brain functions in adolescents receiving fluoxetine (Prozac) or cognitive behavioral therapy (CBT) for anxiety or depression in children/adolescents. All participants will receive interviews to assess how they are doing in general, including his or her general mood, degree of nervousness and behavior. Each participant and one of his or her parents will be interviewed separately and together.
Age: 8 to 17
Consent: Can give consent/assent. (Parents will provide consent; minors will provide assent.)
IQ: All subjects will have IQ greater than 70 (Assessment relies on WASI)
SUBJECTS WITH AN ANXIETY DISORDER
Diagnosis: Current Diagnosis of Social Phobia, Separation Anxiety, or Generalized Anxiety Disorder (Based on K-SADS)
Symptom Severity: Score greater than 9 on PARS (This score was used to enroll subjects in previous trial demonstrating efficacy of an SSRI in pediatric anxiety.)
Clinical Impairment: CGAS less than 60
SUBJECTS WITH A MOOD DISORDER
Diagnosis: Current Diagnosis of Major Depression (Based on K-SADS (juveniles) or SCID (adults))
Clinical Impairment: CGAS less than 60 (juveniles) GAS less than 70 (adults)
Symptom Severity: CDRS Score greater than 39 (juveniles) (This score was used to enroll subjects in previous trials demonstrating efficacy of an SSRI in pediatric depression.)
Consent: Can give consent/assent.
IQ: All subjects will have IQ greater than 70. Assessment relies on WASI.
Any serious medical condition or condition that interferes with fMRI scanning, and for patients electing medication, any condition that increases risk of SSRI treatment. All patients will have complete physical examination. Healthy volunteer participants will be medication-free and have no current serious medical conditions, based on a review of their medical history.
Current use of any psychoactive substance; current suicidal ideation; current diagnosis of attention deficit hyperactivity disorder (ADHD) of sufficient severity to require pharmacotherapy. These factors could complicate treatment with an SSRI. No subject on medication will be accepted into the trial. Subjects will not be taken off of medications to enter the trial.
Current diagnoses: Tourette's, OCD, posttraumatic distress disorder, conduct disorder. These factors may be effected by SSRI treatment, influencing ability to detect effects on anxiety/depression
Past or current history of mania, psychosis, or pervasive developmental disorder. These factors may be effected by SSRI treatment, influencing ability to detect effects on anxiety/depression
Recent use of an SSRI: All subjects must have been free of any SSRI use for at least one month (fluoxetine six months) and must not have been treated with an SSRI for their current depressive episode. This is designed to exclude subjects who have failed a trial of an SSRI for their current episode of major depression.
HEALTHY ADULT SUBJECTS
Any current psychiatric diagnosis. Assessment relies on SCID.
SUBJECTS WITH AN ANXIETY DISORDER
Current Major Depressive Disorder
I have chosen to focus on my healing, and to say only a few words about my long period of suffering. Chances are, you already know – firsthand or secondhand – more than you'd care to know about the suffering! My own suffering had its unique form, but essentially, it was no different from what you probably already know.
Ron Rapee, PhD
Professor, Department of Psychology
Director, Centre for Emotional Health